Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dominic Caruso
Financials
Remicade and Xarelto woes haven't stopped J&J hiking forecast
Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.
Arlene Weintraub
Apr 17, 2018 12:19pm
J&J’s stay-out-of-jail marketing for Invega Sustenna raises eyebrows
Feb 15, 2018 10:16am
J&J takes $14B hit on the way to 'immediate' tax reform windfall
Jan 23, 2018 11:54am
J&J hikes forecast as new meds crank up pharma growth
Jul 19, 2016 7:52am
